43 Objectives: Oxaliplatin can cause hepatic sinusoidal injury and splenomegaly. It remains 44 unknown if the magnitude of injury would differ when oxaliplatin is combined with 45 capecitabine or 5-FU with/without cetuximab. We investigated the impact of 1 st line 46 CAPOX or FOLFOX4 and the additional cetuximab on spleen size, platelet count and liver 47 function in patients with KRAS wild-type metastatic colorectal cancer (mCRC).
Introduction

77
Fluoropyrimidines and oxaliplatin have been used in metastatic colorectal cancer (mCRC) 78 for more than ten years. 1 Oxaliplatin when combined with capecitabine (CAPOX) or 79 infusional 5-FU and folinic acid (FOLFOX regimen) was found equally efficacious in 80 first-line setting. [2] [3] [4] Addition of targeted therapy including anti-epidermal growth factor 81 receptor (EGFR) or anti-vascular endothelial growth factor (VEGF) monoclonal antibody 82 further improves the response rate and overall survival in first and subsequent lines of 83 treatment. [5] [6] [7] [8] [9] [10] [11] The Medical Research Council (MRC) COIN trial, initiated in 2005, was the 84 largest phase III randomized controlled trial which investigated the effect of cetuximab, a 85 monoclonal antibody against EGFR, on overall survival when it was added to oxaliplatin-86 and fluoropyrimidine-based chemotherapy as first-line therapy in mCRC. The choice 87 between oxaliplatin plus infusional 5-FU and oxaliplatin plus capecitabine was not 88 randomized but it was an agreement between patients and treating physicians before 89 treatment commencement. Its first publication reporting its toxicities profiles revealed that 90 severe grade 3/4 diarrhea was observed in 30% of patients who received oxaliplatin and 91 capecitabine, leading to study protocol amendment in 2007 with dose reduction of 92 capecitabine from 1000mg/m 2 to 850mg/m 2 twice daily in future patients. 12 This may be 93 one of the reasons of failure to improve overall survival as published in 2011. 13 At the same 94 time, with growing experience of using oxaliplatin in the past decade, this drug was also 95 6 noted to have close association with hepatic sinusoidal injury and post-hepatectomy 96 morbidity and mortality when given pre-operatively. [14] [15] [16] [17] [18] [19] Moreover increase in spleen size 97 was recently proven an effective biomarker for such hepatic adverse event after 98 oxaliplatin. 20 This adverse hepatic complication is definitely a particular concern to the 99 surgeons and patients when perioperative chemotherapy is increasingly adopted for 100 potentially resectable liver metastases. 21 On the other hand, while bevacizumab was 101 previously shown to carry a protective effect from excessive increase in spleen size, there 102 has been so far no similar report for cetuximab and whether the choice between 5FU and 103 capecitabine would pose any extra effect on the spleen size. 22, 23 Based on all of the above,
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we initiated a prospective study in 2010 to assess the change in spleen size, platelet counts 105 and liver function in patients with KRAS wild-type mCRC treated with either CAPOX or 8 1 week rest period. FOLFOX4 consisted of oxaliplatin 85mg/m 2 infused over two hours 134 concurrently with folinic acid 200mg/m 2 on day 1, followed by bolus 5-FU 400mg/m 2 and 135 continuous 5-FU infusion over 22 hours on day 1 and 2, given as a 2-weekly regimen. For 136 those who also opted for cetuximab, they received an initial loading dose of cetuximab 137 400mg/m 2 infused over 2 hours followed by subsequent 250mg/m 2 over 1 hour once weekly.
138
Dose reduction of chemotherapeutic drugs and cetuximab was in accordance with the 139 departmental guidelines of the treating institution and recommendation from drug 140 manufacturers. Blood tests for hematology and biochemistry were performed before every 141 cycle of treatment and additional blood tests were also arranged if clinically necessary.
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Thrombocytopenia was defined as platelet count less than 150  10 9 /liter. 20 All toxicities 
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Median increase in spleen size was 17.9% (range, -27.7% to +296.6%, P < 0.001) at CT 207 Time Point 1 in whole study population. Patients who received cetuximab had less splenic 208 enlargement than those who did not (median +13.7% vs. +22.7%, P = 0.04) (Fig. 1a) . Also 12 fewer patients (68.9%) who received cetuximab had their spleen enlarged as compared with 210 those who did not receive cetuximab (85.7%, P = 0.04). This was especially seen in those 211 when FOLFOX4 was added to cetuximab than those who had FOLFOX4 alone (median 212 +1.1% vs. +18.0%, P = 0.009), and to a lesser and non-significant extent, in those who had 213 CAPOX plus cetuximab as compared with CAPOX alone (median +23.0% vs. +32.5%, P = 214 0.46) ( Table 2 ).
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Thrombocytopenia was noted in 56 (55.5%) patients with 5.0% being grade 3 events.
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Grade 1 and grade 3 impaired liver function was noted in 51.5% and 1.0% respectively. Again, spleen size was significantly increased with CAPOX plus cetuximab when compared 228 13 with FOLFOX4 plus cetuximab (median +23.0% vs. +1.1%, P = 0.003) (Fig. 1c) . In 229 addition, more patients who received CAPOX plus cetuximab developed splenomegaly than 230 those who received FOLFOX4 plus cetuximab (40.0% vs. 10.0% respectively, P = 0.02).
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An example from one patient whose spleen enlarged after CAPOX plus cetuximab was 232 illustrated in Fig. 2 . Splenomegaly was also significantly associated with thrombocytopenia 233 (P = 0.02) and marginally associated with grade 1 impaired liver function (P = 0.05). (Table 3 ). Univariable analysis revealed that use of capecitabine 241 (OR 4.61, 95% CI, 143%-1493%, P = 0.007), dose intensity of capecitabine (OR 3.81, 95% 242 CI, 126%-1591%, P = 0.02) and cumulative dose of capecitabine per 10000mg increase 243 (OR 1.08, 95% CI, 108%-128%, P = 0.02) correlated with splenomegaly. These three 244 factors also correlated significantly with splenomegaly in multivariable analysis (P = 0.01, 245 P = 0.02 and P = 0.006 respectively) (Table 3) .
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In addition, increase in spleen size and splenomegaly were the only factors which correlated 247 14 with thrombocytopenia in both univariable (OR 4.50, 95% CI, 166%-1210%, P = 0.01 and 248 OR 4.60, 95% CI, 201%-1289%, P = 0.04 respectively) and multivariable analysis (P = 249 0.004 and P = 0.002 respectively). 20 He also confirmed the dose-dependent effect of oxaliplatin on increasing the 267 spleen size in these patients. In his another cohort of patients with liver metastasis in the 268 same study, splenomegaly (with the same definition stated in our study) correlated with 269 moderate to severe hepatic sinusoidal injury in 55% of patients at the time when their liver 270 metastases were resected. The correlation between splenomegaly and thrombocytopenia 271 was also found significant. We are the first demonstrating that use of capecitabine correlated 272 with splenomegaly. More importantly, we also proved that, instead of creatinine clearance, 273 the overall drug intensity and the cumulative dose of capecitabine, which had already 274 incorporated creatinine clearance into consideration, was a more important and reliable 275 factor correlating with splenomegaly.
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Patients who received CAPOX showed a trend of greater splenic enlargement (P = 0.12) 278 and splenomegaly (P = 0.06) as compared with those who received FOLFOX4. Therefore it 279 was reasonable to speculate that capecitabine predisposed to these splenic and hepatic 280 sequelae and subsequent thrombocytopenia secondary to splenic enlargement. In fact, this 281 oral prodrug has to be transformed by carboxylesterase, cytidine deaminase and thymidine 282 phosphorylase before activated to 5-FU, with the first two of the whole three step-wise 283 enzymatic conversions involving substantial hepatic functional workload. We postulated 284 that these frequent and overwhelming enzymatic processes may pose a detriment to liver 285 16 injury and subsequent splenic enlargement, although future confirmation studies are 286 necessary. A meta-analysis of randomized-controlled clinical trials including CRYSTAL,
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OPUS, COIN, NORDIC VII, AIO KRK-0104 and CECOG also echoed that cetuximab 288 should only be used with infusional 5-FU rather than capecitabine or bolus 5-FU in KRAS 289 wild-type mCRC for a better reduction in risk of progression and death. 30 This is not just a 290 concern to oncologists but also surgeons who operate on patients after perioperative was also noted in bevacizumab before. 20, 22, 23, 31 VEGF has been known to regulate activation 302 of matrix metalloproteinase (MMP)-9 by inducing its expression, which in turn, together 303 with MMP-2, triggers the early steps of hepatic sinusoidal injury. 31 Bevacizumab, a 304 17 monoclonal antibody against VEGF, may alleviate this hepatic injury by down-regulation of 305 MMP-9 production. Cetuximab, a monoclonal antibody against EGFR, is not likely to 306 protect the spleen by the same mechanism. Previous studies have demonstrated that weekly 307 dosing of cetuximab with 250mg/m 2 nearly fully saturates its clearance and dose reduction 308 is not necessary in patients with renal and hepatic failure. [32] [33] [34] [35] [36] Perhaps the 309 antibody-dependent and complement-mediated immune responses elicited by cetuximab 310 may modulate the inflammatory response to the hepatic sinusoids, and the exact underlying 311 pathophysiology remains to be deciphered.
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Limitations of the study included non-randomized nature, relative small sample size despite 314 being the largest series ever reported and non-specific timing of splenic volume evaluation 315 due to the variation of cycle duration of different chemotherapeutic regimens. There were 316 also few unbalanced distributions of some of the baseline parameters including lung 317 metastasis, liver metastasis, number and volume of liver metastases, cumulative dose of 318 oxaliplatin, as well as uneven distribution of cumulative dose of capecitabine between 319 CAPOX group and CAPOX plus cetuximab group. However no stratification according to 320 presence and number liver metastasis were performed between FOLFOX and CAPOX with 321 or without cetuximab even in COIN study, as the choice between these two 322 chemotherapeutic regimens were made according to the treating physician and patient's 323 18 own preferences. Despite the difference in the presence, number and volume of liver 324 metastasis, there was no difference in liver impairment scores across each treatment group 325 in our study. Moreover, a previous study demonstrated that mild to moderate liver 326 dysfunction had no clinically significant influence on the pharmacokinetic parameters of 327 capecitabine and its metabolites and there was no need for, a priori, dose reduction of 328 capecitabine in patients with mildly to moderately impaired liver function. 26 It is not 329 practical to conduct a randomized-controlled trial between these two chemotherapeutic 330 regimens in our study again as this has been proven equally efficacious as 1 st line treatment 331 for mCRC previously published in phase III randomized-controlled trials before the 332 initiation of our study. [2] [3] [4] Moreover the role of cetuximab in addition to chemotherapy in 333 KRAS wild-type mCRC had been well established in CRYSTAL and OPUS study. In our 334 study, patients' decision on either FOLFOX4 or CAPOX was mainly based on their concern 335 about financial affordability, hospitalization and their own preference. The decision of 336 adding cetuximab or not was purely their financial consideration as they had to pay at their 337 own cost for cetuximab. In fact, no uneven distribution of the presence, number and volume 338 of liver metastases was found in our patients who received FOLFOX plus cetuximab and 339 CAPOX plus cetuximab (P = 0.24, P = 0.91 and P = 0.17 respectively). Most importantly, 340 unvariable and multivariable analyses did not reveal these factors as predictors of our four 341 treatment outcomes. 
